Some closely watched new drugs grabbed the spotlight at the American Academy of Neurology meeting this week, and plenty of other therapies put up results worth…
What would a migraine headache look like as art? That’s what Allergan is asking sufferers in a new campaign for chronic migraine awareness.
Today, RA studies are taking longer and require more sites to complete. With so few patients actually participating in clinical trials, what does the industry…
The first federal trial over the bleeding risks of Xarelto, Johnson & Johnson and Bayer’s blockbuster anticoagulant, kicks off next week.
Neurocrine is out with its price for Ingrezza—and it’s even higher than some industry watchers expected.
Amid a busy time in Washington, new data on pharmaceutical lobbying show which groups and companies have boosted their spending so far this year.
A big chunk of Brazilian drugmaker Hypermarcas may be up for grabs—and Big Pharma is all over it.
Serum Institute of India CEO Adar Poonawalla struck a deal on Tuesday to pick up a defunct Czech outfit for €72 million.
Facing stepped-up competition for its critical MS franchise, Biogen CEO Michel Vounatsos says his company's ready to try some "innovative" payer…
Yet another key Teva exec could be bowing out in the company’s time of need—and that’s CFO Eyal Desheh.
Novartis’ worst may be behind it—at least, it seemed so to some analysts following Tuesday’s first-quarter earnings announcement.